| RE50267 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | May 18, 22 | Jan 14, 25 | Arena Pharmaceuticals Inc. |
| RE50082 | (5,6-dihydro)pyrimido[4,5-e]indolizines | Jan 20, 22 | Aug 20, 24 | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. |
| RE50083 | URAT1 inhibitor and use thereof | Mar 29, 22 | Aug 20, 24 | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. |
| RE50050 | Pyrimidinedione compounds | Mar 19, 22 | Jul 23, 24 | MyoKardia, Inc. |
| RE50030 | Methods to treat lymphoplasmacytic lymphoma | Nov 24, 21 | Jul 02, 24 | Dana-Farber Cancer Institute, Inc. |
| RE49948 | Aryl ethers and uses thereof | Feb 03, 22 | Apr 30, 24 | Peloton Therapeutics, Inc. |
| RE49931 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | Jan 25, 22 | Apr 23, 24 | Bristol-Myers Squibb Company |
| RE49934 | Inhibitors of cellular metabolic processes | Mar 08, 22 | Apr 23, 24 | Servier Pharmaceuticals LLC |
| RE49918 | Cytotoxic benzodiazepine derivatives | May 10, 21 | Apr 16, 24 | Immunogen Inc. |
| RE49893 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | Jan 25, 22 | Apr 02, 24 | Bristol Myers Squibb Company |
| RE49897 | Salts of a dihydroquinazoline derivative | May 14, 21 | Apr 02, 24 | AIC246 AG & Co. KG |
| RE49880 | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | Jan 25, 22 | Mar 26, 24 | Bristol Myers Squibb Company |
| RE49873 | APP specific bace inhibitors (ASBIs) and uses thereof | Jul 22, 21 | Mar 19, 24 | BUCK INSTITUTE FOR RESEARCH ON AGING |
| RE49860 | Process for preparing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and purification thereof for use as pharmaceutical active ingredient | Nov 03, 20 | Mar 05, 24 | Bayer Pharma Aktiengesellschaft |
| RE49850 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | Feb 02, 22 | Feb 27, 24 | AUCENTRA THERAPEUTICS PTY LTD |
| RE49851 | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | Jul 15, 21 | Feb 27, 24 | Shanghai Allist Pharmaceuticals Co., Ltd. |
| RE49834 | Jak1 selective inhibitors and uses thereof | Nov 15, 21 | Feb 13, 24 | Hangzhou Highlightll Pharmaceutical Co., Ltd. |
| RE49825 | Piperidinyl nociceptin receptor compounds | Apr 30, 21 | Feb 06, 24 | Astraea Therapeutics, LLC |
| RE49826 | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient | Jul 02, 21 | Feb 06, 24 | Bayer Pharma Aktiengesellschaft |
| RE49811 | Sphingosine kinase inhibitors | Mar 07, 22 | Jan 23, 24 | Apogee Biotechnology Corporation |